TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01099423

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: timing of surgery

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: gene expression analysis

Intervention type: GENETIC
Group type: ACTIVE_COMPARATOR
Intervention: gene expression analysis

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: biologic sample preservation procedure

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: biologic sample preservation procedure

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: laboratory biomarker analysis

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: therapeutic conventional surgery
Study: NCT01499355

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mycophenolate mofetil
Description: titrated to a target daily dose of 2 g (1 g twice daily)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: mycophenolate mofetil
Description: titrated to a target daily dose of 2 g (1 g twice daily)
Study: NCT00514761

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD6244
Description: oral vial

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Capecitabine
Description: oral tablet
Study: NCT01569165

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: cleansing teeth after topical fluoride therapy
Description: washing with water 0, 15 or 30 min after APF treatment or cleansing teeth with cotton roll immediately following APF treatment.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: cleansing teeth after topical fluoride therapy
Description: washing with water 0, 15 or 30 min after APF treatment or cleansing teeth with cotton roll immediately following APF treatment.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: cleansing teeth after topical fluoride therapy
Description: washing with water 0, 15 or 30 min after APF treatment or cleansing teeth with cotton roll immediately following APF treatment.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: cleansing teeth after topical fluoride therapy
Description: washing with water 0, 15 or 30 min after APF treatment or cleansing teeth with cotton roll immediately following APF treatment.
Study: NCT02685670

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: anti-CD19 CAR-T
Description: Ex vivo-expanded autologous T cells modified to express CD19 CAR

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Study: NCT01209845

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ketamine
Description: intravenous ketamine(0.2 mg/kg) over 1-2 minutes IV
Study: NCT04350216

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sarilumab 200 MG/1.14 ML Subcutaneous Solution [KEVZARA]
Description: The treatment of sarilumab 200mg will be administered every two weeks subcutaneously.~Each patient will be followed for 6 months from the start of treatment. The last administration of Sarilumab will be 2 weeks before the end of the study.
Study: NCT04549337

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Exercise training
Description: Feasibility and safety of 3 different training protocols will be tested. Therefore the intervention is three different exercise protocols (4X4, 6X1, and 10-20-30). The exercise workload is set according to the patients HRmax or wattmax from a VO2max test at the baseline testing. All training protocols have a duration of 38 minutes and start with a 10-minute warm up and a 3-7-minute cool-down period. The intervals in the training protocols are interspersed with a 3-minute active rest. Therefore the three exercise protocols are matched on duration, and they all fall within the category of high-intensity-interval training.~The accumulated time spend with a heart rate \>85% of HR max will be evaluated to determine the intensity.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise training
Description: Feasibility and safety of 3 different training protocols will be tested. Therefore the intervention is three different exercise protocols (4X4, 6X1, and 10-20-30). The exercise workload is set according to the patients HRmax or wattmax from a VO2max test at the baseline testing. All training protocols have a duration of 38 minutes and start with a 10-minute warm up and a 3-7-minute cool-down period. The intervals in the training protocols are interspersed with a 3-minute active rest. Therefore the three exercise protocols are matched on duration, and they all fall within the category of high-intensity-interval training.~The accumulated time spend with a heart rate \>85% of HR max will be evaluated to determine the intensity.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Exercise training
Description: Feasibility and safety of 3 different training protocols will be tested. Therefore the intervention is three different exercise protocols (4X4, 6X1, and 10-20-30). The exercise workload is set according to the patients HRmax or wattmax from a VO2max test at the baseline testing. All training protocols have a duration of 38 minutes and start with a 10-minute warm up and a 3-7-minute cool-down period. The intervals in the training protocols are interspersed with a 3-minute active rest. Therefore the three exercise protocols are matched on duration, and they all fall within the category of high-intensity-interval training.~The accumulated time spend with a heart rate \>85% of HR max will be evaluated to determine the intensity.
Study: NCT04548414

Intervention type: OTHER
Intervention: No.
Description: This is an observational study with no intervention.
Study: NCT00142051

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nitric oxide
Description: 80 ppm 8 hrs, 40 ppm 8 hrs, 20 ppm 4 hrs, 10 ppm 4 hrs

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: oxygen
Description: oxygen fi02 21% (room air)
Study: NCT02570893

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Adjuvant radiotherapy
Description: Adjuvant radiotherapy (50.4gray/28fraction) followed by 4 cycles of chemotherapy (Paclitaxel and carboplatin) after radical esophagectomy.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Adjuvant radiotherapy
Description: adjuvant radiotherapy (50.4gray/28fraction) only after radical esophagectomy.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel and carboplatin
Study: NCT03473704

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Treatment group (TG)
Description: The Treatment group (TG) will receive the web treatment, which consists of 9 weekly sessions.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Control group (CG)
Description: For ethical reasons, the CG will receive the web treatment once the TG intervention has been completed (as long as it continues to meet the conditions of the study).
Study: NCT03638934

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Videos about ACP
Description: Three videos about advanced care planning are provided for self-education.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Brochure about Life-Sustaining Treatment Act
Description: Brochure about Life-Sustaining Treatment Act are provided for self-education.
Study: NCT02047643

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Computer algorithm to initiate pump suspension
Description: If the computer algorithm senses impending risk for hypoglycemia it sends an alert to an on-site physician to recommend a manual suspension of the subject's insulin pump

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Computer algorithm to initiate pump suspension
Description: If the computer algorithm senses impending risk for hypoglycemia it sends an alert to an on-site physician to recommend a manual suspension of the subject's insulin pump
Study: NCT04629001

Intervention type: DIAGNOSTIC_TEST
Intervention: Covid-19 PCR , IGM
Description: test for Covid-19

Intervention type: DIAGNOSTIC_TEST
Intervention: Covid-19 PCR , IGM
Description: test for Covid-19
Study: NCT01669304

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Verapamil

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sertraline
Study: NCT03533621

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Probiotic - VSL#3
Description: Subjects received a weekly supply of pills for 12 weeks along with support to change their diet to consume more fruits and vegetables. Subjects met with an interventionist weekly to report on pill consumption, stool changes, and get help with changing their dietary behaviors

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo pill - soy protein powder
Description: Subjects received a weekly supply of pills for 12 weeks along with support to change their diet to consume more fruits and vegetables. Subjects met with an interventionist weekly to report on pill consumption, stool changes, and get help with changing their dietary behaviors
Study: NCT03249025

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine
Description: Initial dose of 5.0 mg/kg (based on actual weight, up to maximum dose 600 mg) over 45-60 minutes, followed by increases of 0.5 mg/kg each infusion based on tolerability of side effects, to a maximum total dose of 600 mg. The initial and subsequent dose may be increased or decreased by 20% based on patient comorbidities, age and previous experience

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine
Description: initial dose of 0.25 mg/kg (based on actual weight) over 45-60 minutes (rounded to nearest 5 mg), increased by 10mg each infusion based on tolerability of side effects. The initial and subsequent dose may be increased or decreased by 20% based on patient comorbidities, age and previous experience
Study: NCT04592861

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: carbon ion RT
Description: daily carbon ion radiotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chemotherapy drug
Description: Subjects who receive carbon ion radiotherapy may receive additional chemotherapy afterwards, at the discretion of the treating physicians. Subjects on the control arm are also expected to receive chemotherapy, using a regimen selected by the treating physicians.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chemotherapy drug
Description: Subjects who receive carbon ion radiotherapy may receive additional chemotherapy afterwards, at the discretion of the treating physicians. Subjects on the control arm are also expected to receive chemotherapy, using a regimen selected by the treating physicians.
Study: NCT00827801

Intervention type: BEHAVIORAL
Intervention: MDASI-HF Questionnaire
Description: M. D. Anderson Symptom Inventory - Heart Failure (MDASI-HF) questionnaire rating symptoms given in clinic Day 1, Weeks 4 \& 8.

Intervention type: BEHAVIORAL
Intervention: MDASI-HF Questionnaire
Description: M. D. Anderson Symptom Inventory - Heart Failure (MDASI-HF) questionnaire rating symptoms given in clinic Day 1, Weeks 4 \& 8.
Study: NCT04142450

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CoolSculpting® System
Description: Each participant underwent a single treatment session that was comprised of timed segments of cooling followed by 2 minutes of manual massage.
Study: NCT00389857

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Influenza Virus Vaccine (Fluzone®)
Description: 0.25 mL, Intramuscular (infant/children dose)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Influenza Virus Vaccine (Fluzone®)
Description: 0.25 mL, Intramuscular (infant/children dose)
Study: NCT03436706

Intervention type: OTHER
Intervention: exposure
Description: exposure to chronic stress
Study: NCT01810692

Intervention type: DEVICE
Intervention: Group1:Spiriva® Respimat®
Description: COPD patients using Respimat®

Intervention type: DEVICE
Intervention: Group2:Hirobriz®/Oslif®/Onbrez® Breezhaler®
Description: COPD patients using Breezhaler®®
Study: NCT02467348

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Albumin
Description: Intravenous albumin 8 gms/L of ascitic fluid

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ascitic fluid

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ascitic fluid
Study: NCT00140231

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: r-metHuLeptin
Description: recombinant human leptin

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: r-metHuLeptin
Description: recombinant human leptin

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: placebo
Description: placebo (no active drug)

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo (no active drug)
Study: NCT02537626

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Erchonia ALS Laser
Description: The Erchonia ALS Laser is administered to the subject's frontal cortex, temporal regions and base of the skull 8 times across 4 consecutive weeks, 2 times each week, for 10 minutes of treatment time per administration. The total energy delivered to the subject per procedure administration is 22.5 joules.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Laser
Description: The Placebo Laser is administered to the subject's frontal cortex, temporal regions and base of the skull 8 times across 4 consecutive weeks, 2 times each week, for 10 minutes of treatment time per administration. There is no energy delivered to the subject.
Study: NCT00221247

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Acupuncture
Description: acupuncture
Study: NCT04643509

Intervention type: DEVICE
Intervention: Niccomo
Description: Niccomo monitoring added to pulmonary arterial catheter monitoring
Study: NCT02884726

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986148
Description: Specified dose on specified days
Study: NCT02858830

Intervention type: OTHER
Group type: OTHER
Intervention: High fat mixed meal

Intervention type: OTHER
Group type: OTHER
Intervention: High fat mixed meal
Study: NCT00975507

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Measles, Mumps, Rubella and Varicella (Oka-Merck) Virus Vaccine Live
Description: a single 0.5 mL subcutaneous injection of V221 at Day 0 and Day 90

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Comparator: Placebo
Description: a single 0.5 mL subcutaneous placebo injection at Day 0

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Comparator: Varivax
Description: a single 0.5 mL subcutaneous injection of Varivax at Day 0

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Comparator: M-M-R II
Description: a single 0.5 mL subcutaneous injection of M-M-R II at Day 0
Study: NCT06420895

Intervention type: OTHER
Intervention: Clinical follow-up
Description: Clinical follow-up of patients

Intervention type: OTHER
Intervention: Transthoracic Echocardiogram (TTE)
Description: Transthoracic Echocardiogram

Intervention type: OTHER
Intervention: Magnetic resonance imaging (MRI)
Description: Magnetic resonance imaging

Intervention type: OTHER
Intervention: Transesophageal echocardiogram (TEE)
Description: Transesophageal echocardiogram
Study: NCT03329443

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Spironolactone
Description: each patient will receive 200 mg of spironolactone as per his/her angiography premedications

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral Tablet
Description: Each patient will receive a placebo tablet as per his/her angiography premedications
Study: NCT02259998

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Persantin® new formulation
Study: NCT01499355

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oral corticosteroids
Description: oral corticosteroids (prednisone or equivalent) at a target prednisone dose of 10 mg/day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oral corticosteroids
Description: oral corticosteroids (prednisone or equivalent) at a target prednisone dose of 10 mg/day

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: oral corticosteroids
Description: oral corticosteroids (prednisone or equivalent) at a target prednisone dose of 10 mg/day
Study: NCT02259998

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Persantin® commercial formulation
Study: NCT00293722

Intervention type: DRUG
Intervention: Etanercept
Description: The patients will be treated in accordance with the requirements of the labelling of Enbrel® in Germany. The dosage and duration of therapy is to be determined by the physician to meet the patients' individual needs for treatment.
Study: NCT02530203

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Spinal Cord Stimulation System
Description: High frequency stimulation using a catheter placed in the lumen of the spine to inhibit sympathetic outflow to the heart

Intervention type: DEVICE
Group type: OTHER
Intervention: Holter Recording_ NEMon DR220 Holter Recorders
Description: To measure primary endpoint and most of the secondary endpoints in all the patients enrolled in the study. The recording will start to before CABG procedure and will be stop at day 5.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Holter Recording_ NEMon DR220 Holter Recorders
Description: To measure primary endpoint and most of the secondary endpoints in all the patients enrolled in the study. The recording will start to before CABG procedure and will be stop at day 5.
Study: NCT01062633

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: A, erythritol
Description: 2,5 g 3 times a day

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: xylitol
Description: 2,5 g 3 times a day

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: C, sorbitol
Description: 2,5 g 3 times aday
Study: NCT01446016

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Chloroquine 250mg po daily together with Paclitaxel (Taxane) 175 mg/m2 three hours infusion every three weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Chloroquine 250mg po daily together with docetaxel 75 mg/m2 administered intravenously over one hour every three weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abraxane
Description: Chloroquine 250mg po daily together with Abraxane 260 mg/m2 administered intravenously over 30 minutes every three weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ixabepilone
Description: Chloroquine 250mg po daily together with Ixabepilone is 40 mg/m2 administered intravenously over three hours every three weeks.
Study: NCT04498455

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Prebiotin
Description: Fructo-oligosaccharide dietary supplement powder

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Prebiotin
Description: Fructo-oligosaccharide dietary supplement powder
Study: NCT03492788

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: ECGI-optimized VV-offset
Description: ECGI guided optimization of VV offset programming of CRT device

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Zero VV-offset
Description: Standard-of-care nominal (zero VV-offset) programming of CRT device
Study: NCT04780308

Intervention type: PROCEDURE
Intervention: Pediatric Garthland Type 3 supracondylar humeral fractures fixed by K-wires
Description: The effects of the different types of K-wire configuration on Pediatric Gartland Type 3 supracondylar humeral fractures were evaluated. Pediatric Gartland Type 3 supracondylar humeral fractures operated under general anesthesia with open or closed reduction. After reduction checked by fluoroscopy K-wires applied in different configurations.

Intervention type: PROCEDURE
Intervention: Pediatric Garthland Type 3 supracondylar humeral fractures fixed by K-wires
Description: The effects of the different types of K-wire configuration on Pediatric Gartland Type 3 supracondylar humeral fractures were evaluated. Pediatric Gartland Type 3 supracondylar humeral fractures operated under general anesthesia with open or closed reduction. After reduction checked by fluoroscopy K-wires applied in different configurations.

Intervention type: PROCEDURE
Intervention: Pediatric Garthland Type 3 supracondylar humeral fractures fixed by K-wires
Description: The effects of the different types of K-wire configuration on Pediatric Gartland Type 3 supracondylar humeral fractures were evaluated. Pediatric Gartland Type 3 supracondylar humeral fractures operated under general anesthesia with open or closed reduction. After reduction checked by fluoroscopy K-wires applied in different configurations.

Intervention type: PROCEDURE
Intervention: Pediatric Garthland Type 3 supracondylar humeral fractures fixed by K-wires
Description: The effects of the different types of K-wire configuration on Pediatric Gartland Type 3 supracondylar humeral fractures were evaluated. Pediatric Gartland Type 3 supracondylar humeral fractures operated under general anesthesia with open or closed reduction. After reduction checked by fluoroscopy K-wires applied in different configurations.

Intervention type: PROCEDURE
Intervention: Pediatric Garthland Type 3 supracondylar humeral fractures fixed by K-wires
Description: The effects of the different types of K-wire configuration on Pediatric Gartland Type 3 supracondylar humeral fractures were evaluated. Pediatric Gartland Type 3 supracondylar humeral fractures operated under general anesthesia with open or closed reduction. After reduction checked by fluoroscopy K-wires applied in different configurations.
Study: NCT03113253

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tranexamic Acid

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 0.9% sodium chloride to mimic tranexamic acid
Study: NCT03406260

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lasmiditan
Description: Administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lasmiditan
Description: Administered orally.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered orally.
Study: NCT02322138

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Experimental 1 Infant Formula
Description: Ready to feed infant formula to be fed ad-libitum

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Experimental 2 Infant Formula
Description: Ready to feed infant formula to be fed ad-libitum

Intervention type: OTHER
Group type: OTHER
Intervention: Reference Group
Description: Breast fed ad libitum